January 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor ...

OSAKA, Japan & CAMBRIDGE, Mass., January 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process “The Board of ...

Takeda Pharmaceutical 45020.69%increase; green up pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...

We apologize, but this video has failed to load. “The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber ...

The issuer is solely responsible for the content of this announcement. “The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success ...